Teva Pharmaceutical Industries Limited (NYSE:TEVA) Shares Sold by Deutsche Bank AG

Deutsche Bank AG cut its stake in Teva Pharmaceutical Industries Limited (NYSE:TEVA) by 55.0% in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 2,214,543 shares of the company’s stock after selling 2,710,449 shares during the quarter. Deutsche Bank AG owned about 0.20% of Teva Pharmaceutical Industries worth $48,809,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also modified their holdings of the company. Oarsman Capital Inc. acquired a new position in Teva Pharmaceutical Industries in the fourth quarter valued at approximately $29,000. Marshall & Sterling Wealth Advisors Inc. acquired a new position in Teva Pharmaceutical Industries in the fourth quarter valued at approximately $44,000. Ameliora Wealth Management Ltd. acquired a new position in Teva Pharmaceutical Industries in the fourth quarter valued at approximately $66,000. IFP Advisors Inc lifted its holdings in Teva Pharmaceutical Industries by 96.1% in the fourth quarter. IFP Advisors Inc now owns 3,999 shares of the company’s stock valued at $88,000 after acquiring an additional 1,960 shares during the last quarter. Finally, Quadrant Capital Group LLC lifted its holdings in Teva Pharmaceutical Industries by 27.7% in the fourth quarter. Quadrant Capital Group LLC now owns 4,377 shares of the company’s stock valued at $96,000 after acquiring an additional 949 shares during the last quarter. 54.05% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of equities research analysts have weighed in on the stock. Bank of America lifted their price target on shares of Teva Pharmaceutical Industries from $20.00 to $22.00 and gave the company a “buy” rating in a research report on Thursday, May 8th. UBS Group dropped their price target on shares of Teva Pharmaceutical Industries from $30.00 to $27.00 and set a “buy” rating for the company in a research report on Thursday, January 30th. StockNews.com upgraded shares of Teva Pharmaceutical Industries from a “hold” rating to a “buy” rating in a research report on Wednesday, April 23rd. JPMorgan Chase & Co. raised Teva Pharmaceutical Industries from a “neutral” rating to an “overweight” rating and increased their target price for the stock from $21.00 to $23.00 in a research note on Monday. Finally, Barclays decreased their target price on Teva Pharmaceutical Industries from $28.00 to $26.00 and set an “overweight” rating on the stock in a research note on Thursday, January 30th. Eight analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Buy” and an average price target of $24.43.

Teva Pharmaceutical Industries Stock Performance

NYSE:TEVA opened at $17.48 on Wednesday. The company has a fifty day simple moving average of $15.22 and a two-hundred day simple moving average of $17.44. The company has a market cap of $19.82 billion, a price-to-earnings ratio of -12.06, a price-to-earnings-growth ratio of 1.44 and a beta of 0.62. The company has a quick ratio of 0.75, a current ratio of 0.98 and a debt-to-equity ratio of 2.97. Teva Pharmaceutical Industries Limited has a 52 week low of $12.47 and a 52 week high of $22.80.

Teva Pharmaceutical Industries (NYSE:TEVA) last posted its quarterly earnings results on Wednesday, May 7th. The company reported $0.52 EPS for the quarter, topping the consensus estimate of $0.47 by $0.05. The business had revenue of $3.89 billion during the quarter, compared to the consensus estimate of $3.99 billion. Teva Pharmaceutical Industries had a negative net margin of 9.91% and a positive return on equity of 42.46%. The company’s quarterly revenue was up 1.9% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $0.48 earnings per share. As a group, equities analysts anticipate that Teva Pharmaceutical Industries Limited will post 2.5 earnings per share for the current fiscal year.

Teva Pharmaceutical Industries Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.